Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity by Ruëff, Franziska et al.
PLOS I ONE (0) OPEN a ACCESS Freely available online 
Clinical Effectiveness of Hymenoptera Venom 
Immunotherapy: A Prospective Observational 
Multicenter Study of the European Academy of 
Allergology and Clinical Immunology Interest Group on 
Insect Venom Hypersensitivity 
Franziska Rueffl*, Bernhard Przybilla', Maria Beatrice Bil62, Ulrich Miiller3, Fabian Scheipl4, 
Michael J. Seitz4, Werner Aberer5, Anna Bodzenta-Lukaszyk6, Floriano Bonifazi2, Paolo Campi7, 
Ulf Darsow8, Gabrielle Haeberli3, Thomas Hawranek9, Helmut Kilchenhoff4, Roland Lang9, 
Oliviero Quercia19, Norbert Reider", Peter Schmid-Grendelmeier12, Maurizio Severino7, Gunter 
Johannes Sturm's, Regina Treudler13, Brunello Wilthrich12 
1 Department of Dermatology and Allergology, Ludwig-Maximilians-Universitet, Munchen, Germany, 2 Allergy Unit, Department of Internal Medicine, Allergy, 
Immunology and Respiratory Diseases, Ospedali Riuniti di Ancona, Azienda Ospedaliero-Universitaria, Ancona, Italy, 3 Allergiestation Medizinische Klinik, Spital Ziegler, 
Spitalnetz Bern, Switzerland, 4 Statistical Consulting Unit, Department of Statistics, Ludwig-Maximilians-Universitet, Munchen, Germany, 5 Department of Dermatology, 
Medical University of Graz, Graz, Austria, 6 Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 7 Allergy Clinic, Nuovo 
Ospedale San Giovanni di Dio, Florence, Italy, 8 Department of Dermatology and Allergy Biederstein, Technische Universitet Munchen, and ZAUM - Center for Allergy and 
Environment, Munich, Germany, 9 Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 10 Dipartimento di Medicina Interna, Ospedale per gli 
Infermi, Faenza, Italy, 11 Department of Dermatology, Medical University of Innsbruck, Innsbruck, Austria, 12 Allergiestation, Dermatologische Klinik und Poliklinik, 
Universitatsspital Zurich, Zurich, Switzerland, 13 Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Leipzig, Germany 
Abstract 
Background: Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors. 
Objective: Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters 
with the frequency of VII failure during the maintenance phase. 
Methods: In this observational prospective multicenter study, we followed 357 patients with established honey bee or 
vespid venom allergy after the maintenance dose of VII had been reached. In all patients, VII effectiveness was either 
verified by sting challenge (n = 154) or patient self-reporting of the outcome of a field sting (n = 203). Data were collected on 
BTC, age, gender, preventive use of anti-allergic drugs (oral antihistamines and/or corticosteroids) right after a field sting, 
venom dose, antihypertensive medication, type of venom, side effects during VIT, severity of index sting reaction preceding 
VIT, and duration of VIT. Relative rates were calculated with generalized additive models. 
Results: 22 patients (6.2%) developed generalized symptoms during sting challenge or after a field sting. A strong 
association between the frequency of VIT failure and BTC could be excluded. Due to wide confidence bands, however, 
weaker effects (odds ratios <3) of BTC were still possible, and were also suggested by a selective analysis of patients who 
had a sting challenge. The most important factor associated with VIT failure was a honey bee venom allergy. Preventive use 
of anti-allergic drugs may be associated with a higher protection rate. 
Interpretation: It is unlikely that an elevated BTC has a strong negative effect on the rate of treatment failures. The 
magnitude of the latter, however, may depend on the method of effectiveness assessment. Failure rate is higher in patients 
suffering from bee venom allergy. 
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Introduction 
About 10% of patients suffering from Hymenoptera venom 
allergy present with an elevated baseline tryptase concentration 
(BTC >11.4 pg/L) [1]. BTC is believed to represent the 
individual mast cell burden of a patient. To a large part, increased 
concentrations result from systemic mastocytosis or monoclonal 
mast cell activation syndrome [2]. Elevated BTC may also be 
found in patients with other mast cell diseases like chronic urticaria 
[3], uremic pruritus [4] or in patients with myeloid malignancies 
Pl. Apart from mastocytosis, mast cell number and life span may 
be chronically elevated in unselected allergic patients [5]. 
In allergic patients, it is unequivocally established that an 
increased BTC is a dominating risk factor for severe systemic 
reactions after a field sting by wasps or honey bees [1,6]. During 
venom immunotherapy (VIT), the importance of BTC for severe 
side effects is less clear. A strong, independent association could 
only be shown in patients treated with wasp venom during the 
build-up phase [7]. After VIT, the importance of BTC for 
treatment failure is also controversial. Some consider BTC as an 
important predictor of the chance of VIT failure, and of the risk of 
relapse if VIT is stopped [8], whereas others were unable to find a 
strong association between a high BTC and the effectiveness of 
VIT [9]. For patients with systemic mastocytosis, in whom a 
particularly high BTC (>20.0 ug/1) is an important diagnostic 
criterion, some authors concluded that VIT may reduce the 
frequency of subsequent systemic allergic reactions to a clearly 
lesser extent than in allergic patients not presenting with clonal 
mast cell diseases [10,11]. Others, however, claim that VIT is safe 
and effective in patients with mastocytosis [12]. 
It was the aim of the present prospective international 
multicenter study to determine the importance of BTC and of 
other suspected risk factors for VIT failure during the mainte-
nance phase of VIT. Furthermore, since the precise magnitude of 
the treatment effect is still unknown, the present study also wanted 
to examine the rate of VIT failure in an unselected patient cohort 
suffering from Hymenoptera venom allergy. The first and the 
second part of that study, which examined risk factors for severe 
anaphylactic reactions after a field sting which preceded VIT, or 
for severe side effects during the build-up phase of VIT, were 
published recently [1,7]. 
Methods 
Study Design 
The Tryptase in Hymenoptera Venom Allergy (TIHVA) study 
of the Interest Group on Insect Venom Hypersensitivity of the 
European Academy of Allergology and Clinical Immunology 
(EAACI) is a prospective observational cohort study, which was 
performed in 14 European clinics specialized on the diagnosis and 
treatment of allergic diseases. In patients suffering from Hyme-
noptera venom allergy, we had evaluated risk factors for severe 
systemic reactions after a field sting (before VIT) and during the 
build-up phase of VIT (part I and II of the study) [1,7]. In part III 
of the study, we now present data on the therapeutic effectiveness 
of VIT in a patient subgroup examined during the maintenance 
phase of VIT. Design of the TIHVA study, patient enrolment, 
diagnostic procedures, laboratory tests, data accuracy and 
characteristics of the core population have been presented in 
detail in previous publications [1,7]. 
For the present study, we analyzed those patients in whom the 
effectiveness of VIT could be assessed (either by in-hospital sting 
challenge or by patient-reported reactions to accidental field 
stings). Patients were excluded if they had not undergone a sting 
challenge or if they had not sustained a sting by the culprit insect 
during follow up. Patients who had sustained a field sting and who 
were uncertain about the species of the stinging insect, or in whom 
symptoms were equivocal, or whose history could not precisely be 
obtained, were also excluded from the analysis. We also did not 
incorporate patients into the study who had had a field sting by the 
culprit insect during the build-up phase of VIT. Patients, who 
were allergic to both bee and wasp venom, could not be evaluated 
in the present study. Absence of a double allergy was a prerequisite 
for being enrolled in the core population of this long-term project 
[ 1 ]• 
Venom Immunotherapy 
For the majority of subjects, the maintenance dose was 100 pg. 
In selected high risk patients (bee keepers or other patients with a 
particularly high risk of insect exposure) and in some of the 
patients who had experienced severe side effects during the 
maintenance phase, a maintenance dose of 200 pg was used. 
Indications for using a higher venom dose were not specified. 
PLOS ONE I www.plosone.org 	 2 	 May 2013 I Volume 8 I Issue 5 I e63233 
Effectiveness of Hymenoptera Venom Immunotherapy 
The method and date of effectiveness assessment (in-hospital 
sting challenge or patient-reported reactions to accidental field 
stings) was left to the discretion of the treating study centre. Sting 
challenges were performed according to European guidelines [13] 
which also indicate specific contraindications such as unstable 
internal diseases (asthma, cardiac disease), or pregnancy. Emer-
gency treatment followed specific guidelines. Even in the absence 
of hemodynamic symptoms, all cases developing cutaneous 
symptoms during sting challenge were treated immediately. 
Patient Management during the Maintenance Phase of 
VIT 
At regular time intervals, all patients were seen as outpatients 
for therapy continuation (3 to 5 years after the end of the build-up 
phase). Patients were asked for symptoms which might have 
occurred after a field sting by the culprit insect. For treatment of 
symptoms in the event of being stung by the culprit insect, all 
patients had been provided with an emergency kit including an 
H I -blocking high-dose antihistamine, a corticosteroid and an 
adrenaline auto-injector. In addition, patients with airway 
symptoms received a bronchodilator. Patients had been advised 
to immediately take antihistamines and corticosteroids after a field 
sting, and before the onset of symptoms [14,15]; adrenaline auto-
injectors should only be used in case of a systemic reaction. 
In addition to emergency treatments, preventative measures 
were provided including education (avoidance advice) on how to 
avoid bee and/or wasp stings, and on how to recognise the early 
symptoms of anaphylaxis. 
Baseline and Test Variables 
Besides age (at the time of the sting challenge, or of the first 
eventful or the last uneventful field sting) and gender, we recorded 
preventive use of an emergency medication after a field sting (use 
of oral antihistamines or of antihistamines and corticosteroids 
before the appearance of clinical symptoms), venom dose during 
maintenance therapy, the type of antihypertensive medication, 
which was taken during the sting challenge or field sting and the 
type of venom used for therapy. We also recorded the frequency of 
systemic allergic reactions during the build-up or maintenance 
phase of VIT, and the severity grade (according to Ring [16]) of 
the most severe sting reaction prior to VIT. We furthermore, 
collected information on the time interval between the end of the 
build-up phase of VIT and the day of the sting challenge, or of the 
first eventful or the last uneventful field sting. We also documented 
whether effectiveness had been assessed by sting challenge or 
patient-reported reactions. When taking the patient's history, 
particular attention was paid to the order of events (e.g., 
medication before or after the onset of symptoms). Test variable 
was the baseline serum tryptase concentration (BTC). 
End point of the present analysis was an objective systemic 
reaction during an in-hospital sting challenge or after a field sting 
by the culprit insect. Objective systemic reactions included itching 
and urticaria (but not itching alone), flush and hemodynamic 
shock. At least one of these symptoms must have occurred to 
diagnose a systemic reaction. Three conditions were defined as 
being compatible with signs of a hemodynamic shock: a) heart 
rate>systolic blood pressure when recorded during sting chal-
lenge, b) heart rate>systolic blood pressure registered by an 
emergency physician after a field sting, and c) temporary loss of 
consciousness registered by the patient, by bystanders or by an 
emergency physician after a field sting (assuming that low blood 
pressure leads to unconsciousness). In the absence of hemody-
namic shock, itching/urticaria or flush, we considered dizziness or 
light-headedness an uncertain reaction. Corresponding patients  
were excluded from the analysis. If a patient had already 
experienced systemic symptoms of any kind, and had subsequently 
taken anti-allergic drugs, s/he was counted among those in whom 
VIT had failed, and was not counted among patients who had 
prophylactically taken anti-allergic drugs. 
Patients, who exclusively reported shortness of breath, cough-
ing, or anxiety reactions, and who had recovered without taking 
any emergency medication, were thought to have tolerated the 
venom. Reason for the latter was the finding that, in patients 
allergic to Hymenoptera venom, a self-limiting systemic allergic 
reaction which is exclusively confined to respiratory symptoms is 
an extraordinarily rare event. In honey bee/wasp venom allergy, 
exclusive and self-limiting respiratory symptoms rather result from 
an unspecific psycho-vegetative reaction [17]. 
Statistics 
Categorical variables were expressed as percentage, metric 
variables as median and interquartile range. Selective Compari-
sons between patient groups were made by Fisher's exact test for 
binary variables. 
To estimate smooth (non-linear) effects of metric variables, we 
used penalized regression splines. Smoothing parameters were 
selected by the generalized cross validation criterion. Because of 
low data density, we penalized the effect of binary covariates [18]. 
Covariate-adjusted effects of baseline tryptase concentration 
(BTC) on the effectiveness of VIT were evaluated by multiple 
logistic regression models, which combined separate effects of all 
individual confounding variables (generalized additive models 
(GAMs), [191). GAMs were estimated using an R package [20]. 
For the dependent variable we used the best subset selection 
method to identify a separate starting model which did not include 
the variable BTC [8]. A random effect, however, was included to 
adjust for study centre. Model performance was assessed using 
areas under the curve (AUCs) derived from receiver operating 
characteristic (ROC) analyses of the model [21]. To identify the 
best model we used a stratified 5-fold cross validation with 5 
rounds. To test the tryptase effect, we then added the variable 
"baseline tryptase concentration" to the starting GAM with the 
largest AUC thereby creating the final GAM. Parametric and 
semi-parametric effects for tryptase were estimated. 
To examine whether the effect of BTC depended on the type of 
venom, we used the final GAM to tested interactions between 
venom type and BTC. Furthermore, since early prophylactic use 
of anti-allergic drugs could have prevented development of 
symptoms after a field sting by the culprit insect, we re-estimated 
the final GAM using data which did not include corresponding 
patients to assess the stability of the estimated effects. We also 
constructed another final GAM using only data from patients in 
whom VIT effectiveness had been assessed by sting challenge. 
Results 
Clinical Characteristics of Patients in whom Effectiveness 
of VIT could be Assessed 
The Tryptase in Hymenoptera Venom Allergy study of the 
Interest Group on Insect Venom Hypersensitivity of the EAACI 
recently reported outcomes of 680 patients during the build-up 
phase of VIT [7]. Effectiveness of VIT could be assessed in 357 
patients during the maintenance phase. The majority of patients 
were male (59.1%) and were suffering from wasp venom allergy 
(74.8%). Median age was 45 years (33-59 years). 32 (9.0%) of the 
patients had a BTC >11.4 tg/L (maximum 101.0 µg/L), and 7 
(2.0%) >20 µg/L. 27.2% of the patients had had a grade III or IV 
reaction at the index field sting which preceded immunotherapy. 
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During the build-up or maintenance phase of immunotherapy, 
systemic allergic reactions had occurred in 8.4% of the patients. 
14 patients (3.9%) had been treated with a maintenance venom 
dose of 200 pg. 10 of these patients had been thought to be at a 
particularly high risk and had, therefore, received the 200 pg dose. 
There were only four patients in whom we had started with a 
100 lig dose, and who subsequently were switched to the 200 pg 
dose after systemic allergic reactions had occurred during the 
maintenance phase of WT. 
No follow up was possible in 323 patients. Compared to the 
study group (n = 357 patients), excluded patients were younger 
(age 39.5 years (28-51 years), p<0.001) and were less often allergic 
to wasp venom (63.2%, p = 0.001). The frequency of male patients 
(55.3%, p = 0.321) and of patients presenting with an increased 
BTC (>11.4 pg/1) (10.8%, p = 0.795) was, however, comparable. 
Of those 323 patients, 303 had to be excluded because of a missing 
field sting/sting challenge; in 4 patients there was a significant 
uncertainty regarding the stinging insect, 13 were stung be the 
presumably wrong insect and 3 patients presented with equivocal 
symptoms of their post-sting reaction. Of patients in whom the  
identity of the stinging insect was uncertain or not relevant, none 
had a systemic allergic reaction after the field sting. 
Of patients included into the present study, 154 underwent an 
in-hospital sting challenge (43.1%); the remainder of the patients 
(n = 203) had a field sting by the culprit insect. Median time 
elapsing between the end of build-up and sting challenge/field 
sting by culprit insect was 17 months (10-34 months). 14.3% of the 
patients took various types of antihypertensive medication at the 
time of the sting challenge/field sting. 2.5% of patients were on 
beta-blocker therapy, and 4.2% on Angiotensin converting 
enzyme (ACE)-inhibitor therapy. 
29 patients who were stung by the culprit insect (and who did 
not have a sting challenge) used an emergency medication. These 
patients exclusively took oral antihistamines or antihistamines and 
corticosteroids with intent to prevent allergic reactions. In patients 
assessed by self reporting of field sting reactions (is = 203), 
preventive use of antihistamines or antihistamines and corticoste-
roids was only observed in a minority of these 203 patients 
(14.3%). Of 5 patients who had been stung by the culprit insect 
and who simultaneously presented with a BTC >20 pg/L, only 
Table 1. Distribution of therapy failures during the maintenance phase of VIT with respect to baseline parameters. 
Variable 
Emergency intervention (sting challenge) 
or generalized symptoms (field sting) p value 
No (n=335) Yes 4n=22) 
Gender male 199 (94%) 12 (6%) 0.407 
female 136 (93%) 10 (7%) 
Highest degree of index sting reaction preceding VIT I 	 or II 243 (93%) 17 (7%) 0.420 
Ill or IV 92 (95%) 5 (5%) 
Type of venom wasp 255 (96%) 12 14%) 0.027 
honey bee 80 (89%) 10 (11%) 
Venom dose (bg) during maintenance therapy 100 323 (94%) 20 (6%) 0.211 
200 12 (86%) 2 (14%) 
Side effects during build-up or maintenance phase yes 26 187%) 4 (13%) 0.102 
no 309 (94%) 18 (6%) 
ACE inhibitor medication at sting challenge/field sting yes 15 (100%) 0 (0%) 0.378 
no 320 (94%) 22 (6%) 
Beta -blocker medication at sting challenge/field sting yes 9 (100%) 0 (0%) 0.560 
no 326 (94%) 22 (6%) 
Any antihypertensive medication at sting challenge/field sti 	 g yes 39 (98%) 1 (2%) 0.148 
no 296 (93%) 21 (7%) 
Verification of VIT effectiveness by sting challenge yes 146 (95%) 8 (5%) 0.333 
no 189 (9333) 14 (7%) 
Preventive use of oral antihistamines or antihistamines 
and corticosteroids after the field sting 
yes 29 (100%) 0 (0%) 0.145 
no 306 (93%) 22 (7%) 
Age (years) at sting challenge/field sting according to median - 	 45 172 (93%) 12 (7%) 0.473 
%45 
.163 (94%) 10 (6%) 
Time interval (months) between the end of build up and 
sting challenge/field sting according to median 
172 (92%) 14 (8%) 0.185 
o,17 163 (95%) 8 (5%) 
BTC (pg/I) according to normal value <11_4 304 (93%) 21 (7%) 0.393 
>11.4 31 (93%) 1 (3%) 
Associations are shown between clinical, demographic and therapeutic parameters and the need for an emergency intervention during an in-hospital sting challenge 
or, after a field sting by the culprit insect, the development of any type of generalized symptom. 
doi:10.1371/journal.pone.0063233.t001 
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one took oral antihistamines and corticosteroids right after the 
sting. None of the 29 patients who prophylactically took anti-
allergic drugs had allergic reactions after a field sting. On the other 
hand, generalized reactions developed in 8.1% of the patients (14 
of 174 patients) who had not used an emergency kit after a field 
sting (p = 0.107). Patient groups using or not using an emergency 
medication after a field sting differed slightly: Thus, 20.6% of all 
women, but only 11.1°/0 of all men used such medications 
(p = 0.089). Parameter values of all other variables were not 
significantly different. 
In the whole cohort, 22 patients (6.2%) required an emergency 
intervention during an in-hospital sting challenge or developed, 
after a field sting by the culprit insect, generalized symptoms. This 
failure rate is based on the assumption that preventive use of 
antihistamines or antihistamines and corticosteroids would have in 
fact been unnecessary because of a sufficient protection. However, 
we cannot exclude the possibility that a prophylactic anti-allergic 
medication was effective in preventing a generalized systemic 
reaction which would have been observed without such a therapy. 
Assuming such a bias in patients, who had taken antihistamines or 
antihistamines and corticosteroids after a sting, the frequency of 
VIT failure would be higher maximally amounting to 7.0%. 
Risk Factors for VIT Failure 
Unadjusted results are presented in Table 1. Without consid-
ering confounders, there was no evidence that the frequency of 
VIT failure varied by the venom dose used (100 pg: 5.8%, 200 pg: 
14.3%, p = 0.211), or by the method used to assess effectiveness 
(failure rates according to self-reporting after a field sting: 6.9%, 
according to sting challenge: 5.2%, p = 0.660). 
vrr failure was observed more often in patients receiving a 
honey bee VIT (11% VS. 4% in patients receiving a vespid VIT). 
The difference was even more pronounced in those patients in 
whom VIT effectiveness could be assessed by an in-hospital sting 
0 	 1 	 2 	 3 	 4 
logarithmic baseline tryptase concentration (pg/I) 
Figure 1. Receiver operating characteristic (ROC) curve for the 
final multiple logistic regression model predicting the risk to 
need an emergency intervention during sting challenge or to 
develop generalized symptoms after a field sting. Models were 
tested without including the effect of BTC, or with including a 
smoothed or a linear effect. Corresponding areas under the curve were 
0.7449, 0.7084 or 0.7240. 
doi:10.1371/journal.pone.0063233.9001 
false positive rate 
Figure 2. Smooth function and pointwise 95% confidence 
bands (dashed lines) for the effect of baseline tryptase 
concentration on the risk to need an emergency intervention 
during sting challenge or to develop generalized symptoms 
after a field sting (final multivariate generalized additive 
model). Odds ratios are referred to those of the median of tryptase 
concentration. The odds ratio of the latter has been set at 1. 
doi:10.1371/journal.pone.0063233.g002 
challenge (19% vs. 1%, p<0.001). There was also a tendency for a 
lower protection rate in patients, who had had a systemic allergic 
reaction during the build up or maintenance phase of VIT (13% 
vs. 6%, p = 0.102), whereas preventive use of oral antihistamines 
or antihistamines and corticosteroids appeared to reduce the 
frequency of generalized symptoms after a field sting (see above). 
An increased BTC (>11.4 pg/L) did not increase the frequency of 
VII failure (3% vs. 7% in patients with a BTC 5-11.4 pg/L, 
p = 0.393). 
When selecting variables for the starting GAM (which did not 
include the variable BTC), a random study centre effect was 
retained in the model. Consequently, the final starting model was 
adjusted for such an effect. According to AUG values, the best 
model was that which included the variables "therapy with honey 
bee venom", "assessment of effectiveness by sting challenge", 
"ACE-inhibitor medication at sting challenge/field sting" and " 
preventive use of oral antihistamines or antihistamines and 
corticosteroids after the field sting" (AUC = 0.7182). 
After adjustment for the other confounders, we did not observe 
a significant association between BTC and the risk for VIT failure 
(Figure 1). Irrespective from the type of effect examined (smooth or 
linear), incorporation of BTC also did not increase the AUC of the 
starting model (Figure 2). The width of the confidence bands 
(Figure 1), however, allowed us to rule out major effects of BTC 
(e.g., in comparison to a reference patient with a WIC of 4.3 pg/L 
(the sample mean), the odds ratio for a patient with a BTC of 
20 )..ig/L is unlikely to be higher than 2.7). 
Inclusion of the variable BTC into the starting model did not 
appreciably change the importance of other confounders (Table 2). 
Thus, a therapy with honey bee venom remained a potential 
predictor for VIT failure, whereas use of an emergency medication 
after the field sting, and assessment of effectiveness by sting 
challenge presumably had lowered this risk. The latter finding is 
remarkable, since in the unadjusted analysis we could not find an 
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Table 2. Results of the final generalized additive model for the risk to need an emergency intervention during an in-hospital sting 
challenge or, after a field sting by the culprit insect, to develop any type of generalized symptom. 
Variable p value odds ratio 95% confidence interval 
Therapy with honey bee venom 0.100.. 2.209 0.860 5.675 
Verification of VIT effectiveness by sting challenge 0.070 0.344 0.109 1.091 
ACE-inhibitor medication 0.495 0.461 0.050 4.265 
Preventive use of oral antihistamines or antihistamines and corticosteroids after the field sting 0.101 0.203 0.030 1.362 
Those variables are shown, which were selected according to the modeling procedure. P-values and widths of confidence intervals are biased downwards due to the 
effect of subset selection. 
doi:10.1371/journal.pone.0063233.t002 
association between the type of effectiveness assessment and VIT 
failure emphasizing the importance of considering other con-
founders when estimating the predictive power of an individual 
parameter. The comparably small number of patients in whom 
treatment failed, however, prevented the identification of clearly 
significant effects (p-values between 0.05 and 0.1). 
The variable "ACE-inhibitor medication at sting challenge/ 
field sting" was also retained in the final model. However, the 
precise importance of this variable for risk prediction remains 
unknown, because of the large uncertainty associated with its 
estimated effect. Finally, several other variables were not selected 
for the final model by the AUC based algorithm indicating the 
prognostic unimportance of age, gender, venom dose during 
maintenance therapy, other types of antihypertensive medication, 
frequency of systemic allergic reactions during the build-up or 
maintenance phase of VIT, severity of the most severe sting 
reaction prior to VIT, and duration of VIT. 
There was also no evidence that the effect of BTC varied 
between wasp and honey bee VIT. After including interactions 
between venom type and BTC into an extended model, the 
specific association between venom type and BTC was not 
significant (p>0.5). Furthermore, incorporation of different types 
of BTC effects (linear or smooth) did not increase the AUC of the 
extended model. 
Since we found evidence that preventive use of antihistamines 
or antihistamines and corticosteroids might have prevented 
subsequent allergic reactions (thereby possibly obscuring the 
assessment of VIT effectiveness), the statistical analysis was 
repeated after exclusion of patients having used this self-
medication. Corresponding models and odds ratios, however, 
remained virtually unchanged. 
Since results obtained by self-reporting of field sting reactions 
might be biased, and since we found evidence that verification of 
VIT effectiveness depends on the method used, we performed an 
additional statistical analysis using only data from patients who 
had a sting challenge to assess vrr effectiveness. In that subgroup 
analysis, estimation of the variable "therapy with honey bee 
venom" yielded an odds ratio of 28.1 (95% confidence interval 
3.65--217, p = 0.001), and estimation of the variable "BTC" an 
odds ratio of 2.18 (after a logarithmic transformation; 95% 
confidence interval 0.68--7.10, p = 0.183). These estimates were 
much more pronounced than those based on the full data set. 
Discussion 
Our study is the largest to evaluate the importance of BTC in 
the serum and of a variety of other suspected risk factors for 
treatment failure during the maintenance phase of VIT. In our 
study, VIT failure was either defined as an objective generalized 
symptom during an in-hospital sting challenge or as a systemic  
reaction after a field sting by the culprit insect. We found that the 
rate of VIT failure may vary between 6.2% and 7.0% (if it is 
assumed that a systemic allergic reaction would have occurred in 
all patients who had taken preventive anti-allergic drugs). 
The effectiveness of VIT is beyond doubt. Two systematic 
reviews [22,23] and one meta-analysis [24] have concluded that 
VIT is effective in preventing future systemic reactions to venom 
in patients with hymenoptera venom allergy. The magnitude of 
the effect, however, is highly controversial. According to numerous 
randomized, quasi experimental or non-comparative studies, the 
reported rates of VIT. failure range between 0 and 36% [25]. The 
quality of these studies is mostly poor due to small sample size, and 
all studies are single centre studies reflecting the experience of a 
single institution thereby preventing a generalization of the results. 
Furthermore, there is substantial heterogeneity in terms of 
differences in venom extracts and concentrations, differences in 
administration methods (updosing and/or maintenance programs, 
type and length of treatment), differences in the type of 
effectiveness assessment, in timing of re-stings and in the 
proportion of patients being re-stung. Hockenhull et al [25] 
recently pooled data from nine randomized and non-randomized 
studies which had used Pharmalgen® for VIT. In these studies, 
VIT effectiveness had either been assessed by sting provocation or 
by accidental field stings. Furthermore, there was no evidence that 
field sting reactions could have been obscured by an anti allergic 
emergency pre-treatment. The authors found a rate of VIT failure 
of 6.5% (22 systemic reactions in 337 patients). This rate 
corresponds closely to our findings and suggests that, in unselected 
patients and despite the above limitations, the effectiveness of VIT 
is excellent and highly reproducible. 
The key finding of our study is that there was no strong 
association between BTC and the frequency of treatment failure 
during the maintenance phase of VIT. Due to the width of the 
confidence bands, however, smaller effects of BTC cannot be 
excluded. It has recently been speculated that there might be 
negative effects of an elevated BTC/mastocytosis on the success 
rate of VIT [10]. A systematic review pooled data from seven 
observational studies examining VIA: effectiveness in mastocytosis. 
The authors found that 28% of the treated patients (23 of 82 
patients) had a systemic reaction to a re-sting [10]. This failure rate 
is almost five times higher than the average failure rate of 6% 
found in unselected cohorts (including the one in the present 
study). According to our data, however, the magnitude of the 
BTC/mastocytosis effect might have been overestimated in that 
analysis, which could not adjust results to potential confounders. 
The size of our cohort would have been sufficient to detect a 
more than 4-fold increase of the rate of VIT failure due to an 
elevated BTC (>11.4 ug/1). Assuming that about 10% of patients 
present with an increased BTC (>11.4 gel), and assuming 
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further that the probability of VIT failure is about 5% for patients, 
who have a normal BTC, it may he calculated that a study would 
have to analyse at least 331 patients to detect such an increase in 
frequency (two-sided type I error, 5 percent; power, 80 percent). 
Our data provide some evidence, however, that weaker effects of 
BTC might indeed exist. A subgroup analysis in patients in whom 
we had used sting challenge to asses VIT effectiveness revealed 
such a weak BTC effect (OR 2.18 for a 2.7 fold increase of BTC) 
which was retained in the final statistical model and which, for 
reasons discussed below, might be more reliable than the effect 
estimated for the whole cohort. Consequently, our findings suggest 
that a minority of patients (presumably those presenting with a 
particularly high BTC) may not benefit from a standard VIT to 
the same extent as patients with a normal BTC. 
Several other conclusions may be derived from our results. In 
accordance with numerous other studies, bee venom allergy was 
an independent predictor for VIT failure. A systematic review 
found that only 0 9% of patients allergic to wasp venom, but 
about 20% of bee venom allergic patients still reacted to a sting 
challenge with the culprit insect [11]. It is also established that 
immunotherapy with bee venom is a major risk factor for severe 
side effects during the build-up phase of VIT [7,11]. On the other 
hand, we and others have shown that, before VIT, honey bee 
venom allergy is an important predictor for a lower risk of a severe 
systemic reaction after a field sting [1,26,27]. Consequently, the 
worse results associated with honey bee venom immunotherapy 
must be attributed to the treatment itself. Thus far, it is entirely 
unclear why a treatment with honey bee venom is associated with 
a higher rate of side effects and treatment failures. We have 
recently speculated that this phenomenon relates to the amount of 
venom dose applied during therapy. In honey bee and wasp VIT 
the total number of therapeutic injections is the same. In 
comparison to wasp VIT and to the amount of wasp venom 
emitted during a field sting, patients receiving a honey bee venom 
immunotherapy are, however, exposed to a significantly greater 
number of injections, which provide subclinical amounts of venom 
thereby possibly favouring pro-allergic reactions during therapy, 
and treatment failures [71. Conversely, it is also possible that wasp 
VIT is more effective than bee VIT because there are marked 
differences in the amount of venom emitted during a field sting 
(honey bee: 50 to 100 1.tg; wasp: 3 to 5 p.g), whereas the amount of 
venom applied during the maintenance phase of VIT is identical. 
Therefore, compared to field sting conditions, patients allergic to 
wasp venom receive a much greater dose possibly resulting in a 
better protection. 
Another interesting finding of our study was that the method 
which had been used to assess effectiveness correlated with the 
chance of WI' failure. VIT seemed to be less effective when 
evaluated by patient self-reporting (systemic allergic reactions after 
a field sting) than when evaluated by in-hospital sting challenge. 
Thus, the adjusted frequency of systemic allergic reactions was 
lower during sting challenge than after a field sting. Differences 
between those two methods used to provoke an allergic reaction 
are well established and have been demonstrated again recently by 
studies assessing the effectiveness of VIT. in patients with 
mastocytosis [10,13]. 
To explain these divergent results two different hypotheses have 
been put forward. The first assumes that the risk for severe allergic 
reactions is greater during normal life than when being 
deliberately tested in well-prepared patients in a highly artificial 
environment excluding those who have contraindications for sting 
challenge [13]. In such a setting this bias would artificially reduce 
the frequency of VIT failures. The second hypothesis focuses on 
the historical assessment of preceding symptoms. Within such a  
procedure a bias may exist affecting the reliability of information 
obtained by self-reporting after a field sting. There are numerous 
misconceptions related to a patient's comprehension, recall, 
evaluation and expression [28,29]. Despite VIT, a new sting 
may be preconceived by the patient as a risk factor of future severe 
allergic reactions making him inflate the importance of post-sting 
symptoms. Thus, subjective symptoms after a field sting can be 
described as severe by patients but can be viewed as subjective and 
not significant during sting challenge. Such a mechanism would 
artificially increase the frequency of VIT failures after a field sting. 
The relative importance of those two hypothesis is unknown but 
allergists tend to favour the second one [30]. 
Three other aspects of our results deserve a specific comment. 
When analyzing the use of self medication after a field sting by the 
culprit insect, we found an association with the rate of VIT failure 
(Table 2). Although significance was marginal, this effect was 
retained in the final statistical model emphasizing the prognostic 
importance of this variable. Preventive use of oral antihistamines 
or antihistamines and corticosteroids appeared to decrease the risk 
of a systemic allergic reaction thereby supporting corresponding 
guideline and practice parameter recommendations [8,11,31]. It 
should be noted, however, that this finding is also subject to a 
recall bias. Patients feeling reassured by self-medication might 
have been less likely to report symptoms. 
Only about 14% of the patients used oral antihistamines or 
antihistamines and corticosteroids to prevent allergic reactions 
after a field sting. This finding precisely corresponds to the 
depressingly low frequency (about 14%) with which oral antial-
lergic drugs are taken after unselected severe allergic reactions in 
the community of German speaking countries [32]. These low 
frequencies reveal an extraordinarily poor patient compliance and 
underscore the need for an intensified patient education and 
training. 
Finally, we found no evidence that side effects during the build-
up or maintenance phase correlated with treatment effectiveness. 
During VIT, the strongest predictor for severe side effects is a 
therapy with honey bee venom [7]. Since the latter variable is also 
associated with the chance of VIT failure, it is likely that the 
importance of the type of venom for treatment success outweighed 
the importance of side effects during VIT. 
There was also no association between the duration of Vfl: and 
the frequency of VIT failure. It is commonly believed that the 
length of VIT correlates with the protection rate. A recent study, 
however, suggested that in the majority of allergic patients VIT is 
effective within a week after the maintenance dose has been 
achieved [33]. In most of the patients in our study, however, the 
effectiveness of VIT could be only assessed between months 10 
and 34 of maintenance therapy. It appears that at least during this 
time span the protection rate largely remains unchanged. 
Strengths and Limitations of the Study 
The major strength of this study is the large number of patients, 
and the prospective and multicentre design allowing a general-
ization of obtained findings. The study, however, is also subject to 
several limitations. Only about half of the original patient cohort 
which had had a VII' [7] was evaluable in terms of effectiveness 
assessment (either by sting challenge or self reporting of outcomes 
after a field sting). This might represent a selection bias, 
particularly in view of the fact that, compared to patients in the 
present study, excluded patients differed in terms of age and 
frequency of bee/wasp venom allergy. Furthermore, self reporting 
implies errors concerning the correct identification of the insect 
involved in a field sting, the correct reporting of symptoms, and 
the true amount of venom delivered by the sting. In addition, the 
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small number of events NIT failures) prevented a thorough 
analysis of BTC and of a variety of other variables possibly 
important for the protection rate. Finally, it is also possible that a 
portion of the absent effect of BTC was due to an analytical error. 
A certain, albeit small number of patients might have presented 
with heterophilic antibodies which may falsely increase BTC 
[34,35]. 
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